nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—Melatonin—CALR—esophageal cancer	0.189	0.726	CrCbGaD
Midodrine—Melatonin—CYP1B1—esophageal cancer	0.0412	0.158	CrCbGaD
Midodrine—Melatonin—CYP19A1—esophageal cancer	0.0303	0.116	CrCbGaD
Midodrine—Pain—Carboplatin—esophageal cancer	0.00948	0.0306	CcSEcCtD
Midodrine—Hyperaesthesia—Capecitabine—esophageal cancer	0.00856	0.0276	CcSEcCtD
Midodrine—Irritability—Cisplatin—esophageal cancer	0.00631	0.0204	CcSEcCtD
Midodrine—Sleep disorder—Capecitabine—esophageal cancer	0.00563	0.0182	CcSEcCtD
Midodrine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00558	0.018	CcSEcCtD
Midodrine—Abdominal discomfort—Cisplatin—esophageal cancer	0.00548	0.0177	CcSEcCtD
Midodrine—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00529	0.0171	CcSEcCtD
Midodrine—Stomatitis—Cisplatin—esophageal cancer	0.00497	0.016	CcSEcCtD
Midodrine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00482	0.0155	CcSEcCtD
Midodrine—Bradycardia—Cisplatin—esophageal cancer	0.00466	0.015	CcSEcCtD
Midodrine—Irritability—Capecitabine—esophageal cancer	0.00465	0.015	CcSEcCtD
Midodrine—Urinary retention—Capecitabine—esophageal cancer	0.00464	0.015	CcSEcCtD
Midodrine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00452	0.0146	CcSEcCtD
Midodrine—Urethral disorder—Cisplatin—esophageal cancer	0.00448	0.0145	CcSEcCtD
Midodrine—Dry skin—Capecitabine—esophageal cancer	0.00447	0.0144	CcSEcCtD
Midodrine—Flushing—Cisplatin—esophageal cancer	0.00425	0.0137	CcSEcCtD
Midodrine—Cardiac disorder—Cisplatin—esophageal cancer	0.00425	0.0137	CcSEcCtD
Midodrine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00404	0.013	CcSEcCtD
Midodrine—Dysuria—Capecitabine—esophageal cancer	0.00394	0.0127	CcSEcCtD
Midodrine—Flatulence—Cisplatin—esophageal cancer	0.00392	0.0127	CcSEcCtD
Midodrine—Muscle spasms—Cisplatin—esophageal cancer	0.00383	0.0124	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00372	0.012	CcSEcCtD
Midodrine—Stomatitis—Capecitabine—esophageal cancer	0.00366	0.0118	CcSEcCtD
Midodrine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00355	0.0115	CcSEcCtD
Midodrine—Irritability—Methotrexate—esophageal cancer	0.00346	0.0112	CcSEcCtD
Midodrine—Bradycardia—Capecitabine—esophageal cancer	0.00343	0.0111	CcSEcCtD
Midodrine—Anxiety—Cisplatin—esophageal cancer	0.00338	0.0109	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00337	0.0109	CcSEcCtD
Midodrine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00333	0.0107	CcSEcCtD
Midodrine—Urethral disorder—Capecitabine—esophageal cancer	0.00331	0.0107	CcSEcCtD
Midodrine—Erythema multiforme—Capecitabine—esophageal cancer	0.00319	0.0103	CcSEcCtD
Midodrine—Nervous system disorder—Cisplatin—esophageal cancer	0.00319	0.0103	CcSEcCtD
Midodrine—Tachycardia—Cisplatin—esophageal cancer	0.00317	0.0102	CcSEcCtD
Midodrine—Skin disorder—Cisplatin—esophageal cancer	0.00316	0.0102	CcSEcCtD
Midodrine—Cardiac disorder—Capecitabine—esophageal cancer	0.00313	0.0101	CcSEcCtD
Midodrine—Flushing—Capecitabine—esophageal cancer	0.00313	0.0101	CcSEcCtD
Midodrine—Angiopathy—Capecitabine—esophageal cancer	0.00306	0.00987	CcSEcCtD
Midodrine—Chills—Capecitabine—esophageal cancer	0.00303	0.00976	CcSEcCtD
Midodrine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00301	0.0097	CcSEcCtD
Midodrine—Mental disorder—Capecitabine—esophageal cancer	0.00295	0.00953	CcSEcCtD
Midodrine—Dysuria—Methotrexate—esophageal cancer	0.00293	0.00946	CcSEcCtD
Midodrine—Paraesthesia—Cisplatin—esophageal cancer	0.00292	0.00942	CcSEcCtD
Midodrine—Dyspnoea—Cisplatin—esophageal cancer	0.0029	0.00935	CcSEcCtD
Midodrine—Flatulence—Capecitabine—esophageal cancer	0.00289	0.00933	CcSEcCtD
Midodrine—Back pain—Capecitabine—esophageal cancer	0.00284	0.00916	CcSEcCtD
Midodrine—Muscle spasms—Capecitabine—esophageal cancer	0.00282	0.00911	CcSEcCtD
Midodrine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00281	0.00905	CcSEcCtD
Midodrine—Pain—Cisplatin—esophageal cancer	0.00278	0.00897	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00277	0.00894	CcSEcCtD
Midodrine—Stomatitis—Methotrexate—esophageal cancer	0.00273	0.00879	CcSEcCtD
Midodrine—Feeling abnormal—Cisplatin—esophageal cancer	0.00268	0.00864	CcSEcCtD
Midodrine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00264	0.00853	CcSEcCtD
Midodrine—Hypertension—Capecitabine—esophageal cancer	0.00253	0.00818	CcSEcCtD
Midodrine—Anxiety—Capecitabine—esophageal cancer	0.00249	0.00804	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00248	0.00801	CcSEcCtD
Midodrine—Urinary tract disorder—Methotrexate—esophageal cancer	0.00248	0.008	CcSEcCtD
Midodrine—Urethral disorder—Methotrexate—esophageal cancer	0.00246	0.00794	CcSEcCtD
Midodrine—Dry mouth—Capecitabine—esophageal cancer	0.00244	0.00789	CcSEcCtD
Midodrine—Confusional state—Capecitabine—esophageal cancer	0.00242	0.00779	CcSEcCtD
Midodrine—Erythema multiforme—Methotrexate—esophageal cancer	0.00237	0.00766	CcSEcCtD
Midodrine—Nervous system disorder—Capecitabine—esophageal cancer	0.00235	0.00758	CcSEcCtD
Midodrine—Tachycardia—Capecitabine—esophageal cancer	0.00234	0.00754	CcSEcCtD
Midodrine—Asthenia—Cisplatin—esophageal cancer	0.00233	0.00752	CcSEcCtD
Midodrine—Cardiac disorder—Methotrexate—esophageal cancer	0.00233	0.00752	CcSEcCtD
Midodrine—Skin disorder—Capecitabine—esophageal cancer	0.00233	0.00751	CcSEcCtD
Midodrine—Angiopathy—Methotrexate—esophageal cancer	0.00228	0.00735	CcSEcCtD
Midodrine—Chills—Methotrexate—esophageal cancer	0.00225	0.00727	CcSEcCtD
Midodrine—Mental disorder—Methotrexate—esophageal cancer	0.0022	0.0071	CcSEcCtD
Midodrine—Insomnia—Capecitabine—esophageal cancer	0.00217	0.00699	CcSEcCtD
Midodrine—Paraesthesia—Capecitabine—esophageal cancer	0.00215	0.00694	CcSEcCtD
Midodrine—Dyspnoea—Capecitabine—esophageal cancer	0.00214	0.00689	CcSEcCtD
Midodrine—Back pain—Methotrexate—esophageal cancer	0.00211	0.00682	CcSEcCtD
Midodrine—Dyspepsia—Capecitabine—esophageal cancer	0.00211	0.0068	CcSEcCtD
Midodrine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00207	0.00667	CcSEcCtD
Midodrine—Rash—Cisplatin—esophageal cancer	0.00205	0.00661	CcSEcCtD
Midodrine—Pain—Capecitabine—esophageal cancer	0.00205	0.00661	CcSEcCtD
Midodrine—Dermatitis—Cisplatin—esophageal cancer	0.00205	0.00661	CcSEcCtD
Midodrine—Feeling abnormal—Capecitabine—esophageal cancer	0.00197	0.00637	CcSEcCtD
Midodrine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00196	0.00632	CcSEcCtD
Midodrine—Nausea—Cisplatin—esophageal cancer	0.00193	0.00623	CcSEcCtD
Midodrine—Abdominal pain—Capecitabine—esophageal cancer	0.00189	0.00611	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00185	0.00596	CcSEcCtD
Midodrine—Confusional state—Methotrexate—esophageal cancer	0.0018	0.0058	CcSEcCtD
Midodrine—Nervous system disorder—Methotrexate—esophageal cancer	0.00175	0.00564	CcSEcCtD
Midodrine—Skin disorder—Methotrexate—esophageal cancer	0.00173	0.00559	CcSEcCtD
Midodrine—Asthenia—Capecitabine—esophageal cancer	0.00172	0.00555	CcSEcCtD
Midodrine—Pruritus—Capecitabine—esophageal cancer	0.0017	0.00547	CcSEcCtD
Midodrine—Insomnia—Methotrexate—esophageal cancer	0.00161	0.0052	CcSEcCtD
Midodrine—Paraesthesia—Methotrexate—esophageal cancer	0.0016	0.00517	CcSEcCtD
Midodrine—Dyspnoea—Methotrexate—esophageal cancer	0.00159	0.00513	CcSEcCtD
Midodrine—Somnolence—Methotrexate—esophageal cancer	0.00159	0.00512	CcSEcCtD
Midodrine—Dizziness—Capecitabine—esophageal cancer	0.00158	0.00511	CcSEcCtD
Midodrine—Dyspepsia—Methotrexate—esophageal cancer	0.00157	0.00506	CcSEcCtD
Midodrine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00154	0.00497	CcSEcCtD
Midodrine—Pain—Methotrexate—esophageal cancer	0.00153	0.00492	CcSEcCtD
Midodrine—Rash—Capecitabine—esophageal cancer	0.00151	0.00487	CcSEcCtD
Midodrine—Dermatitis—Capecitabine—esophageal cancer	0.00151	0.00487	CcSEcCtD
Midodrine—Headache—Capecitabine—esophageal cancer	0.0015	0.00484	CcSEcCtD
Midodrine—Feeling abnormal—Methotrexate—esophageal cancer	0.00147	0.00474	CcSEcCtD
Midodrine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00146	0.00471	CcSEcCtD
Midodrine—Nausea—Capecitabine—esophageal cancer	0.00142	0.00459	CcSEcCtD
Midodrine—Abdominal pain—Methotrexate—esophageal cancer	0.00141	0.00455	CcSEcCtD
Midodrine—Asthenia—Methotrexate—esophageal cancer	0.00128	0.00413	CcSEcCtD
Midodrine—Pruritus—Methotrexate—esophageal cancer	0.00126	0.00407	CcSEcCtD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00119	0.00277	CbGpPWpGaD
Midodrine—Dizziness—Methotrexate—esophageal cancer	0.00118	0.0038	CcSEcCtD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00117	0.00272	CbGpPWpGaD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00116	0.0027	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.00115	0.00269	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GDI2—esophageal cancer	0.00115	0.00267	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00115	0.00267	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00114	0.00266	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—GNG7—esophageal cancer	0.00114	0.00265	CbGpPWpGaD
Midodrine—Rash—Methotrexate—esophageal cancer	0.00112	0.00363	CcSEcCtD
Midodrine—Dermatitis—Methotrexate—esophageal cancer	0.00112	0.00362	CcSEcCtD
Midodrine—ADRA1D—GPCR ligand binding—ANXA1—esophageal cancer	0.00112	0.00261	CbGpPWpGaD
Midodrine—Headache—Methotrexate—esophageal cancer	0.00112	0.0036	CcSEcCtD
Midodrine—ADRA1D—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	0.00111	0.00258	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—SST—esophageal cancer	0.00109	0.00254	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00109	0.00253	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.00108	0.00252	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—GHRL—esophageal cancer	0.00106	0.00247	CbGpPWpGaD
Midodrine—Nausea—Methotrexate—esophageal cancer	0.00106	0.00342	CcSEcCtD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00106	0.00246	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00104	0.00242	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00103	0.0024	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00102	0.00237	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—GNG7—esophageal cancer	0.00101	0.00235	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—CXCL2—esophageal cancer	0.001	0.00233	CbGpPWpGaD
Midodrine—ADRA1B—AMPK Signaling—PIK3CA—esophageal cancer	0.000985	0.00229	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GDI2—esophageal cancer	0.000954	0.00222	CbGpPWpGaD
Midodrine—ADRA1B—AMPK Signaling—TP53—esophageal cancer	0.000953	0.00222	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—ANXA1—esophageal cancer	0.000931	0.00217	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000924	0.00215	CbGpPWpGaD
Midodrine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	0.000922	0.00215	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.00092	0.00214	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000907	0.00211	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—SST—esophageal cancer	0.000905	0.00211	CbGpPWpGaD
Midodrine—SLC15A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000905	0.00211	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AKAP13—esophageal cancer	0.000889	0.00207	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—CXCL2—esophageal cancer	0.000889	0.00207	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—GHRL—esophageal cancer	0.000882	0.00205	CbGpPWpGaD
Midodrine—ADRA1A—AMPK Signaling—PIK3CA—esophageal cancer	0.000875	0.00204	CbGpPWpGaD
Midodrine—SLC15A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000868	0.00202	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000865	0.00201	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000853	0.00199	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GDI2—esophageal cancer	0.000847	0.00197	CbGpPWpGaD
Midodrine—ADRA1A—AMPK Signaling—TP53—esophageal cancer	0.000847	0.00197	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KMT2D—esophageal cancer	0.000831	0.00193	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—ANXA1—esophageal cancer	0.000827	0.00192	CbGpPWpGaD
Midodrine—ADRA1A—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	0.000819	0.00191	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PDE4D—esophageal cancer	0.000814	0.00189	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AKAP13—esophageal cancer	0.000808	0.00188	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—SST—esophageal cancer	0.000804	0.00187	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—GHRL—esophageal cancer	0.000784	0.00182	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—GNG7—esophageal cancer	0.000774	0.0018	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ADCYAP1—esophageal cancer	0.00074	0.00172	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PDE4D—esophageal cancer	0.000739	0.00172	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AKAP13—esophageal cancer	0.000738	0.00172	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—GNG7—esophageal cancer	0.000703	0.00164	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KMT2D—esophageal cancer	0.00069	0.0016	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—CXCL2—esophageal cancer	0.000682	0.00159	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—WWOX—esophageal cancer	0.000677	0.00158	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PDE4D—esophageal cancer	0.000675	0.00157	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AKAP13—esophageal cancer	0.00067	0.00156	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000656	0.00153	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FKBP1A—esophageal cancer	0.000644	0.0015	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—GNG7—esophageal cancer	0.000642	0.00149	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—ANXA1—esophageal cancer	0.000634	0.00148	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—WIF1—esophageal cancer	0.00063	0.00147	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCL2—esophageal cancer	0.000619	0.00144	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—SST—esophageal cancer	0.000617	0.00143	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ADCYAP1—esophageal cancer	0.000615	0.00143	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PDE4D—esophageal cancer	0.000613	0.00143	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KMT2D—esophageal cancer	0.000612	0.00143	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—GHRL—esophageal cancer	0.000601	0.0014	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.0006	0.0014	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AKAP13—esophageal cancer	0.000595	0.00139	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—GNG7—esophageal cancer	0.000583	0.00136	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CSNK1A1—esophageal cancer	0.000581	0.00135	CbGpPWpGaD
Midodrine—SLC15A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00058	0.00135	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—ANXA1—esophageal cancer	0.000576	0.00134	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—GNG7—esophageal cancer	0.00057	0.00133	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCL2—esophageal cancer	0.000566	0.00132	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—WWOX—esophageal cancer	0.000562	0.00131	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—SST—esophageal cancer	0.00056	0.0013	CbGpPWpGaD
Midodrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000551	0.00128	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000546	0.00127	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—GHRL—esophageal cancer	0.000546	0.00127	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PDE4D—esophageal cancer	0.000545	0.00127	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PFN1—esophageal cancer	0.000543	0.00126	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FKBP1A—esophageal cancer	0.000535	0.00124	CbGpPWpGaD
Midodrine—ADRA1D—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000535	0.00124	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—ANXA1—esophageal cancer	0.000526	0.00122	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—WIF1—esophageal cancer	0.000523	0.00122	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—GNG7—esophageal cancer	0.000518	0.00121	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCL2—esophageal cancer	0.000514	0.0012	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—SST—esophageal cancer	0.000512	0.00119	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000503	0.00117	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—WWOX—esophageal cancer	0.000499	0.00116	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—GHRL—esophageal cancer	0.000499	0.00116	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ELMO1—esophageal cancer	0.000488	0.00114	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000482	0.00112	CbGpPWpGaD
Midodrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000478	0.00111	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—ANXA1—esophageal cancer	0.000478	0.00111	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AKAP13—esophageal cancer	0.000477	0.00111	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FKBP1A—esophageal cancer	0.000475	0.00111	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000467	0.00109	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000465	0.00108	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000465	0.00108	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—SST—esophageal cancer	0.000465	0.00108	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—WIF1—esophageal cancer	0.000464	0.00108	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000457	0.00106	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCL2—esophageal cancer	0.000456	0.00106	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—SST—esophageal cancer	0.000455	0.00106	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—GHRL—esophageal cancer	0.000453	0.00105	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PFN1—esophageal cancer	0.000451	0.00105	CbGpPWpGaD
Midodrine—ADRA1B—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000444	0.00103	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—GHRL—esophageal cancer	0.000443	0.00103	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00044	0.00102	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PDE4D—esophageal cancer	0.000436	0.00102	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000428	0.000997	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—ANXA1—esophageal cancer	0.000424	0.000988	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GNG7—esophageal cancer	0.000415	0.000966	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—SST—esophageal cancer	0.000413	0.000961	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000406	0.000945	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ELMO1—esophageal cancer	0.000405	0.000943	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—GHRL—esophageal cancer	0.000402	0.000936	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PFN1—esophageal cancer	0.000401	0.000933	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000397	0.000924	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKAP13—esophageal cancer	0.000396	0.000922	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000395	0.00092	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000395	0.00092	CbGpPWpGaD
Midodrine—ADRA1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000394	0.000917	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—XIAP—esophageal cancer	0.000389	0.000905	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CTNNA1—esophageal cancer	0.000368	0.000856	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCL2—esophageal cancer	0.000366	0.000851	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000365	0.000851	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDE4D—esophageal cancer	0.000362	0.000843	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000362	0.000841	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ELMO1—esophageal cancer	0.00036	0.000838	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000353	0.00082	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKAP13—esophageal cancer	0.000352	0.000819	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GNG7—esophageal cancer	0.000345	0.000802	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PSME2—esophageal cancer	0.000342	0.000795	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PSME1—esophageal cancer	0.000342	0.000795	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ANXA1—esophageal cancer	0.00034	0.000791	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000336	0.000782	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000336	0.000782	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SST—esophageal cancer	0.000331	0.00077	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000325	0.000756	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—XIAP—esophageal cancer	0.000323	0.000751	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH3—esophageal cancer	0.000322	0.00075	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—GHRL—esophageal cancer	0.000322	0.00075	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDE4D—esophageal cancer	0.000322	0.000749	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FBXW7—esophageal cancer	0.000317	0.000738	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GNG7—esophageal cancer	0.000306	0.000712	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CTNNA1—esophageal cancer	0.000305	0.000711	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCL2—esophageal cancer	0.000304	0.000706	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000295	0.000686	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH2—esophageal cancer	0.000289	0.000673	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—XIAP—esophageal cancer	0.000287	0.000667	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PSME1—esophageal cancer	0.000284	0.00066	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PSME2—esophageal cancer	0.000284	0.00066	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ANXA1—esophageal cancer	0.000282	0.000657	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000282	0.000656	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SST—esophageal cancer	0.000275	0.000639	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000274	0.000638	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000271	0.000631	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	0.00027	0.000628	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—GHRL—esophageal cancer	0.000268	0.000623	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH3—esophageal cancer	0.000268	0.000623	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000267	0.000621	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FBXW7—esophageal cancer	0.000263	0.000613	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TGFBR2—esophageal cancer	0.000256	0.000597	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000255	0.000593	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000255	0.000593	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	0.000252	0.000586	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	0.000252	0.000586	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	0.000251	0.000583	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000244	0.000568	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SST—esophageal cancer	0.000244	0.000568	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SMAD4—esophageal cancer	0.000243	0.000565	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH2—esophageal cancer	0.00024	0.000558	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	0.000238	0.000553	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000238	0.000553	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000235	0.000547	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	0.000234	0.000544	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000233	0.000542	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000222	0.000516	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000213	0.000496	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFBR2—esophageal cancer	0.000213	0.000495	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000208	0.000483	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SMAD4—esophageal cancer	0.000201	0.000469	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HIF1A—esophageal cancer	0.000199	0.000462	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000197	0.00046	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000195	0.000454	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KDR—esophageal cancer	0.00019	0.000442	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	0.000189	0.00044	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000185	0.000431	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000185	0.000431	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000182	0.000424	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000182	0.000424	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	0.000179	0.000417	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH1—esophageal cancer	0.000179	0.000416	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	0.000165	0.000384	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CREBBP—esophageal cancer	0.000162	0.000378	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—EGFR—esophageal cancer	0.000159	0.000371	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KDR—esophageal cancer	0.000158	0.000367	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000157	0.000366	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000152	0.000355	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	0.000149	0.000346	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000148	0.000344	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	0.000146	0.000341	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOS3—esophageal cancer	0.000145	0.000338	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	0.00014	0.000326	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	0.000138	0.000322	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	0.000136	0.000316	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000135	0.000314	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	0.000135	0.000313	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	0.000132	0.000308	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	0.000132	0.000307	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.00013	0.000302	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000126	0.000294	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	0.000121	0.000281	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	0.00012	0.000279	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	0.00012	0.000278	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	0.000118	0.000274	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	0.000116	0.00027	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	0.000115	0.000267	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	0.000113	0.000262	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000112	0.000261	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EP300—esophageal cancer	0.00011	0.000257	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	0.000107	0.000249	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	0.000102	0.000237	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	0.0001	0.000233	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	9.96e-05	0.000232	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	9.64e-05	0.000224	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MYC—esophageal cancer	9.63e-05	0.000224	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	9.42e-05	0.000219	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EP300—esophageal cancer	9.17e-05	0.000213	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	8.85e-05	0.000206	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CREBBP—esophageal cancer	8.66e-05	0.000202	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	8.56e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	8.17e-05	0.00019	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	8.15e-05	0.00019	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MYC—esophageal cancer	7.99e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TP53—esophageal cancer	7.91e-05	0.000184	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	7.82e-05	0.000182	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NOS3—esophageal cancer	7.75e-05	0.00018	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	7.1e-05	0.000165	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.09e-05	0.000165	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	6.94e-05	0.000162	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	6.78e-05	0.000158	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TP53—esophageal cancer	6.56e-05	0.000153	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	6.03e-05	0.00014	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—EP300—esophageal cancer	5.9e-05	0.000137	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	5.83e-05	0.000136	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.36e-05	0.000102	CbGpPWpGaD
